{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:35:20Z","timestamp":1791855320493,"version":"4.3.4"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20190226"],"award-info":[{"award-number":["20190226"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["2018-1256"],"award-info":[{"award-number":["2018-1256"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021071","name":"Faculty of Medicine and Health, University of Sydney","doi-asserted-by":"publisher","award":["Executive Dean Scholarship in Personalised Medicine"],"award-info":[{"award-number":["Executive Dean Scholarship in Personalised Medicine"]}],"id":[{"id":"10.13039\/501100021071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40262-024-01346-7","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:02:19Z","timestamp":1706799739000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?"],"prefix":"10.1007","volume":"63","author":[{"given":"Lina","family":"Davies Forsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Yejin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"2","key":"1346_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/106002809102500210","volume":"25","author":"GG Zhanel","year":"1991","unstructured":"Zhanel GG, Hoban DJ, Harding GK. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991;25(2):153\u201363.","journal-title":"DICP"},{"issue":"33 Suppl 3","key":"1346_CR2","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1086\/321841","volume":"15","author":"X Zhao","year":"2001","unstructured":"Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;15(33 Suppl 3):S147\u201356.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1346_CR3","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1086\/424849","volume":"190","author":"T Gumbo","year":"2004","unstructured":"Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190(9):1642\u201351.","journal-title":"J Infect Dis"},{"issue":"6","key":"1346_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106180","volume":"56","author":"S Imani","year":"2020","unstructured":"Imani S, Alffenaar JW, Cotta MO, Daveson K, van Hal S, Lau C, et al. Therapeutic drug monitoring of commonly used anti-infective agents: a nationwide cross-sectional survey of Australian hospital practices. Int J Antimicrob Agents. 2020;56(6): 106180.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"1346_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/cid\/ciw677","volume":"64","author":"JC Alffenaar","year":"2017","unstructured":"Alffenaar JC, Tiberi S, Verbeeck RK, Heysell SK, Grobusch MP. Therapeutic drug monitoring in tuberculosis: practical application for physicians. Clin Infect Dis. 2017;64(1):104\u20135.","journal-title":"Clin Infect Dis"},{"key":"1346_CR6","doi-asserted-by":"crossref","unstructured":"Hallworth M. CHAPTER 39\u2014Therapeutic drug monitoring. In: Marshall WJ, Lapsley M, Day AP, Ayling RM, editors. Clinical biochemistry: metabolic and clinical aspects (Third Edition): Churchill Livingstone; 2014. p. 767\u201386.","DOI":"10.1016\/B978-0-7020-5140-1.00039-0"},{"issue":"11","key":"1346_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"1346_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases Society of America. Clin Infect Dis. 2015;62(4):e1\u201350.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1346_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper(). Intensive Care Med. 2020;46(6):1127\u201353.","journal-title":"Intensive Care Med"},{"issue":"8","key":"1346_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"1346_CR11","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1007\/s00134-022-06921-9","volume":"48","author":"TMJ Ewoldt","year":"2022","unstructured":"Ewoldt TMJ, Abdulla A, Rietdijk WJR, Muller AE, de Winter BCM, Hunfeld NGM, et al. Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial. Intensive Care Med. 2022;48(12):1760\u201371.","journal-title":"Intensive Care Med"},{"issue":"8","key":"1346_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.cmi.2020.03.008","volume":"26","author":"AG M\u00e4rtson","year":"2020","unstructured":"M\u00e4rtson AG, Sturkenboom MGG, Stojanova J, Cattaneo D, Hope W, Marriott D, et al. How to design a study to evaluate therapeutic drug monitoring in infectious diseases? Clin Microbiol Infect. 2020;26(8):1008\u201316.","journal-title":"Clin Microbiol Infect."},{"key":"1346_CR13","volume-title":"Drug excretion. Reference module in biomedical sciences","author":"EF Barreto","year":"2021","unstructured":"Barreto EF, Larson TR, Koubek EJ. Drug excretion. Reference module in biomedical sciences. Oxford: Elsevier; 2021."},{"key":"1346_CR14","unstructured":"al. JMRe. Rang & Dale's Pharmacology, 10th Edition. Chapter 9. Absorption and distribution of drugs. 2023."},{"issue":"6","key":"1346_CR15","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cpt19741661052","volume":"16","author":"SB Matin","year":"1974","unstructured":"Matin SB, Wan SH, Karam JH. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther. 1974;16(6):1052\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1346_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","volume":"36","author":"H Liu","year":"1999","unstructured":"Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999;36(6):453\u201370.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"1346_CR17","doi-asserted-by":"publisher","first-page":"15123","DOI":"10.1038\/bdjteam.2015.123","volume":"2","author":"M Dodds","year":"2015","unstructured":"Dodds M, Roland S, Edgar M, Thornhill M. Saliva A review of its role in maintaining oral health and preventing dental disease. BDJ Team. 2015;2(1):15123.","journal-title":"BDJ Team."},{"issue":"5","key":"1346_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0003-9969(98)00020-X","volume":"43","author":"DA Kavanagh","year":"1998","unstructured":"Kavanagh DA, O\u2019Mullane DM, Smeeton N. Variation of salivary flow rate in adolescents. Arch Oral Biol. 1998;43(5):347\u201352.","journal-title":"Arch Oral Biol"},{"issue":"6","key":"1346_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/jac\/dkab057","volume":"76","author":"S Mohamed","year":"2021","unstructured":"Mohamed S, Mvungi HC, Sariko M, Rao P, Mbelele P, Jongedijk EM, et al. Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania. J Antimicrob Chemother. 2021;76(6):1547\u201352.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"1346_CR20","doi-asserted-by":"publisher","first-page":"2102787","DOI":"10.1183\/13993003.02787-2021","volume":"59","author":"I Margineanu","year":"2022","unstructured":"Margineanu I, Akkerman O, Cattaneo D, Goletti D, Marriott DJE, Migliori GB, et al. Practices of therapeutic drug monitoring in tuberculosis: an international survey. Eur Respir J. 2022;59(4):2102787.","journal-title":"Eur Respir J."},{"issue":"2","key":"1346_CR21","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bcp.14995","volume":"88","author":"I Sandaradura","year":"2022","unstructured":"Sandaradura I, Alffenaar JW, Cotta MO, Daveson K, Day RO, Van Hal S, et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: availability, performance and barriers to implementation. Br J Clin Pharmacol. 2022;88(2):669\u201379.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1346_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/FTD.0000000000000936","volume":"44","author":"HY Kim","year":"2022","unstructured":"Kim HY, Byashalira KC, Heysell SK, M\u00e4rtson AG, Mpagama SG, Rao P, et al. Therapeutic drug monitoring of anti-infective drugs: implementation strategies for 3 different scenarios. Ther Drug Monit. 2022;44(1):3\u201310.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"1346_CR23","first-page":"582","volume":"34","author":"HJ Galena","year":"1992","unstructured":"Galena HJ. Complications occurring from diagnostic venipuncture. J Fam Pract. 1992;34(5):582\u20134.","journal-title":"J Fam Pract"},{"key":"1346_CR24","doi-asserted-by":"crossref","unstructured":"Roth T, Fiedler S, Mihai S, Parsch H. Determination of meropenem levels in human serum by high-performance liquid chromatography with ultraviolet detection. Biomed Chromatogr BMC. 2016;31.","DOI":"10.1002\/bmc.3880"},{"issue":"2","key":"1346_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2125.1983.tb01496.x","volume":"15","author":"A Hutchings","year":"1983","unstructured":"Hutchings A, Monie RD, Spragg B, Routledge PA. A method to prevent the loss of isoniazid and acetylisoniazid in human plasma. Br J Clin Pharmacol. 1983;15(2):263\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1346_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1331\/108658002763316851","volume":"42","author":"QA Xu","year":"2002","unstructured":"Xu QA, Trissel LA, Saenz CA, Ingram DS, Williams KY. Stability of three cephalosporin antibiotics in AutoDose Infusion System bags. J Am Pharm Assoc (Wash). 2002;42(3):428\u201331.","journal-title":"J Am Pharm Assoc (Wash)"},{"issue":"6","key":"1346_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2165\/00003088-199630060-00003","volume":"30","author":"JD Wright","year":"1996","unstructured":"Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet. 1996;30(6):445\u201362.","journal-title":"Clin Pharmacokinet."},{"key":"1346_CR28","doi-asserted-by":"crossref","unstructured":"Pranger AD, Altena Rv, Aarnoutse RE, Soolingen Dv, Uges DRA, Kosterink JGW, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. 2011:erj01766-2010.","DOI":"10.1183\/09031936.00176610"},{"issue":"8","key":"1346_CR29","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","volume":"67","author":"F Pea","year":"2012","unstructured":"Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67(8):2034\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"1346_CR30","unstructured":"World Health Organisation. The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: treatment\u2014drug-resistant tuberculosis treatment 2022 update. https:\/\/www.who.int\/publications\/i\/item\/9789240063129. Accessed 3 Apr 2023."},{"issue":"5","key":"1346_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106783","volume":"61","author":"C Lau","year":"2023","unstructured":"Lau C, Marriott D, Bui J, Figtree M, Gould M, Chubaty A, et al. LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents. 2023;61(5): 106783.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1346_CR32","doi-asserted-by":"publisher","first-page":"1901903","DOI":"10.1183\/13993003.01903-2019","volume":"55","author":"SHJ van den Elsen","year":"2020","unstructured":"van den Elsen SHJ, Akkerman OW, Jongedijk EM, Wessels M, Ghimire S, van der Werf TS, et al. Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. Eur Respir J. 2020;55(5):1901903.","journal-title":"Eur Respir J."},{"issue":"8","key":"1346_CR33","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1128\/AAC.00558-13","volume":"57","author":"MS Bolhuis","year":"2013","unstructured":"Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3676\u201380.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1346_CR34","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1128\/JCM.01248-17","volume":"55","author":"SHJ van den Elsen","year":"2017","unstructured":"van den Elsen SHJ, van der Laan T, Akkerman OW, van der Zanden AGM, Alffenaar JC, van Soolingen D. Membrane filtration is suitable for reliable elimination of mycobacterium tuberculosis from saliva for therapeutic drug monitoring. J Clin Microbiol. 2017;55(11):3292\u20133.","journal-title":"J Clin Microbiol"},{"issue":"7","key":"1346_CR35","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkab075","volume":"76","author":"HY Kim","year":"2021","unstructured":"Kim HY, Ruiter E, Jongedijk EM, Ak HK, Marais BJ, Pk B, et al. Saliva-based linezolid monitoring on a mobile UV spectrophotometer. J Antimicrob Chemother. 2021;76(7):1786\u201392.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"1346_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00007691-199410000-00001","volume":"16","author":"R Gorodischer","year":"1994","unstructured":"Gorodischer R, Burtin P, Hwang P, Levine M, Koren G. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;16(5):437\u201343.","journal-title":"Ther Drug Monit"},{"key":"1346_CR37","doi-asserted-by":"crossref","unstructured":"Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self-testing as an invaluable tool in fighting the COVID-19 pandemic. J Prim Care Community Health. 2021;12:21501327211047782.","DOI":"10.1177\/21501327211047782"},{"key":"1346_CR38","doi-asserted-by":"crossref","unstructured":"Alffenaar J-WC, Jongedijk EM, van Winkel CAJ, Sariko M, Heysell SK, Mpagama S, et al. A mobile microvolume UV\/visible light spectrophotometer for the measurement of levofloxacin in saliva. J Antimicrob Chemother. 2020;76(2):423\u20139.","DOI":"10.1093\/jac\/dkaa420"},{"issue":"1","key":"1346_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2165\/00003088-197803010-00003","volume":"3","author":"M Danhof","year":"1978","unstructured":"Danhof M, Breimer DD. Therapeutic drug monitoring in saliva. Clin Pharmacokinet. 1978;3(1):39\u201357.","journal-title":"Clin Pharmacokinet."},{"issue":"1","key":"1346_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s002280050250","volume":"52","author":"K Sagawa","year":"1997","unstructured":"Sagawa K, Mohri K, Shimada S, Shimizu M, Muramatsu J. Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations. Eur J Clin Pharmacol. 1997;52(1):65\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1346_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1528-1157.1979.tb04774.x","volume":"20","author":"K Nishihara","year":"1979","unstructured":"Nishihara K, Uchino K, Saitoh Y, Honda Y, Nakagawa F, Tamura Z. Estimation of plasma unbound phenobarbital concentration by using mixed saliva. Epilepsia. 1979;20(1):37\u201345.","journal-title":"Epilepsia"},{"issue":"3","key":"1346_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40262-015-0321-z","volume":"55","author":"TK Kiang","year":"2016","unstructured":"Kiang TK, Ensom MH. A qualitative review on the pharmacokinetics of antibiotics in saliva: implications on clinical pharmacokinetic monitoring in humans. Clin Pharmacokinet. 2016;55(3):313\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1346_CR43","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1080\/0036554021000026963","volume":"34","author":"O Burkhardt","year":"2002","unstructured":"Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002;34(12):898\u2013903.","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"1346_CR44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jac\/dkw412","volume":"72","author":"J Fonsart","year":"2017","unstructured":"Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, et al. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017;72(2):478\u201385.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1346_CR45","first-page":"3","volume":"92","author":"B Kelentey","year":"1999","unstructured":"Kelentey B, Lenkey B, Poti S, Olveti E, Gyulahazi J, Redl P, et al. Analysis of secretion into the saliva of cefoxitin (Mefoxin), imipenem (Tienam) and meropenem (Meronem). Fogorv Sz. 1999;92(1):3\u201310.","journal-title":"Fogorv Sz"},{"issue":"1","key":"1346_CR46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/FTD.0000000000000462","volume":"40","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit. 2018;40(1):17\u201337.","journal-title":"Ther Drug Monit"},{"key":"1346_CR47","doi-asserted-by":"crossref","unstructured":"Arabyat M, Abdul-Sattar A, Al-Fararjah F, Al-Ghazawi A, Rabayah A, Al-Hasassnah R, et al. Therapeutic drug monitoring of vancomycin in Jordanian patients. Development of physiologically-based pharmacokinetic (PBPK) model and validation of class II drugs of salivary excretion classification system (SECS). Drug Res. 2022;72(08):441\u20138.","DOI":"10.1055\/a-1852-5391"},{"issue":"1","key":"1346_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.joms.2013.06.214","volume":"72","author":"M Troeltzsch","year":"2014","unstructured":"Troeltzsch M, Pache C, Probst FA, Troeltzsch M, Ehrenfeld M, Otto S. Antibiotic concentrations in saliva: a systematic review of the literature, with clinical implications for the treatment of sialadenitis. J Oral Maxillofac Surg. 2014;72(1):67\u201375.","journal-title":"J Oral Maxillofac Surg"},{"key":"1346_CR49","unstructured":"European Medicines Agency. ICH M10 on bioanalytical method validation\u2014Scientific guideline. 2022, The Netherlands. https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline. Accessed 3 Apr 2023."},{"key":"1346_CR50","unstructured":"U.S. Department of Health and Human Services Food Drug Administration (FDA). Bioanalytical Method Validation: Guidance for Industry. MD, U.S., 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry. Accessed 3 Apr 2023."},{"key":"1346_CR51","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Bioanalytical method validation and study sample analysis M10. 2022. https:\/\/www.ich.org\/page\/multidisciplinary-guidelines.  Accessed 3 Apr 2023."},{"issue":"1","key":"1346_CR52","first-page":"172024","volume":"51","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, et al. Lack of penetration of amikacin into saliva of tuberculosis patients. Eur Respir J. 2018;51(1):172024.","journal-title":"Eur Respir J."},{"issue":"694","key":"1346_CR53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1749-6632.1993.tb18340.x","volume":"20","author":"WJ Jusko","year":"1993","unstructured":"Jusko WJ, Milsap RL. Pharmacokinetic principles of drug distribution in saliva. Ann N Y Acad Sci. 1993;20(694):36\u201347.","journal-title":"Ann N Y Acad Sci"},{"key":"1346_CR54","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3389\/fphar.2020.00894","volume":"11","author":"HY Kim","year":"2020","unstructured":"Kim HY, M\u00e4rtson AG, Dreesen E, Spriet I, Wicha SG, McLachlan AJ, et al. Saliva for precision dosing of antifungal drugs: saliva population PK model for voriconazole based on a systematic review. Front Pharmacol. 2020;11:894.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1346_CR55","first-page":"449","volume":"33","author":"G Arredondo","year":"1995","unstructured":"Arredondo G, Calvo R, Marcos F, Mart\u00ednez-Jord\u00e1 R, Suarez E. Protein binding of itraconazole and fluconazole in patients with cancer. Int J Clin Pharmacol Ther. 1995;33(8):449\u201352.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"1346_CR56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/jac\/45.1.95","volume":"45","author":"LJ Cross","year":"2000","unstructured":"Cross LJ, Bagg J, Oliver D, Warnock D. Serum itraconazole concentrations and clinical responses in Candida-associated denture stomatitis patients treated with itraconazole solution and itraconazole capsules. J Antimicrob Chemother. 2000;45(1):95\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"2\u20133","key":"1346_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.forsciint.2004.10.026","volume":"150","author":"JK Aps","year":"2005","unstructured":"Aps JK, Martens LC. Review: the physiology of saliva and transfer of drugs into saliva. Forens Sci Int. 2005;150(2\u20133):119\u201331.","journal-title":"Forens Sci Int"},{"issue":"4","key":"1346_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","volume":"41","author":"S Capiau","year":"2019","unstructured":"Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019;41(4):409\u201330.","journal-title":"Ther Drug Monit"},{"issue":"17","key":"1346_CR59","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s40265-021-01618-7","volume":"81","author":"TR Zijp","year":"2021","unstructured":"Zijp TR, Izzah Z, \u00c5berg C, Gan CT, Bakker SJL, Touw DJ, et al. Clinical value of emerging bioanalytical methods for drug measurements: a scoping review of their applicability for medication adherence and therapeutic drug monitoring. Drugs. 2021;81(17):1983\u20132002.","journal-title":"Drugs"},{"issue":"4","key":"1346_CR60","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1111\/bcp.15105","volume":"88","author":"A Samb","year":"2022","unstructured":"Samb A, Kruizinga M, Tallahi Y, van Esdonk M, van Heel W, Driessen G, et al. Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: a prospective population pharmacokinetic and simulation study. Br J Clin Pharmacol. 2022;88(4):1845\u201355.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1346_CR61","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/cid\/ciu1146","volume":"60","author":"JW Alffenaar","year":"2015","unstructured":"Alffenaar JW, Gumbo T, Aarnoutse RE. Acquired drug resistance: we can do more than we think! Clin Infect Dis. 2015;60(6):969\u201370.","journal-title":"Clin Infect Dis"},{"key":"1346_CR62","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2020.00620","volume":"11","author":"W Kantasiripitak","year":"2020","unstructured":"Kantasiripitak W, Van Daele R, Gijsen M, Ferrante M, Spriet I, Dreesen E. Software tools for model-informed precision dosing: how well do they satisfy the needs? Front Pharmacol. 2020;11:620.","journal-title":"Front Pharmacol."},{"issue":"3","key":"1346_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0714.1990.tb00809.x","volume":"19","author":"ID Mandel","year":"1990","unstructured":"Mandel ID. The diagnostic uses of saliva. J Oral Pathol Med. 1990;19(3):119\u201325.","journal-title":"J Oral Pathol Med"},{"key":"1346_CR64","unstructured":"European Medicines Agency, Guideline on Bioanalytical Method Validation, 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf. Accessed 3 Apr 2023."},{"issue":"11","key":"1346_CR65","doi-asserted-by":"publisher","first-page":"773","DOI":"10.4321\/S1130-01082004001100005","volume":"96","author":"C Fenoll-Palomares","year":"2004","unstructured":"Fenoll-Palomares C, Munoz Montagud JV, Sanchiz V, Herreros B, Hernandez V, Minguez M, et al. Unstimulated salivary flow rate, pH and buffer capacity of saliva in healthy volunteers. Rev Esp Enferm Dig. 2004;96(11):773\u201383.","journal-title":"Rev Esp Enferm Dig"},{"issue":"4","key":"1346_CR66","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4103\/0972-124X.118317","volume":"17","author":"S Baliga","year":"2013","unstructured":"Baliga S, Muglikar S, Kale R. Salivary pH: a diagnostic biomarker. J Indian Soc Periodontol. 2013;17(4):461\u20135.","journal-title":"J Indian Soc Periodontol."},{"key":"1346_CR67","unstructured":"Clinical and Laboratory Standards Institute. Measurement procedure comparison and bias estimation using patient samples, 2013. https:\/\/clsi.org\/media\/2293\/ep09ed3ce_sample.pdf. Accessed 3 Apr 2023."},{"issue":"6 Pt 1","key":"1346_CR68","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/clinchem\/45.6.882","volume":"45","author":"K Linnet","year":"1999","unstructured":"Linnet K. Necessary sample size for method comparison studies based on regression analysis. Clin Chem. 1999;45(6 Pt 1):882\u201394.","journal-title":"Clin Chem"},{"issue":"3","key":"1346_CR69","first-page":"147","volume":"27","author":"OH Drummer","year":"2006","unstructured":"Drummer OH. Drug testing in oral fluid. Clin Biochem Rev. 2006;27(3):147.","journal-title":"Clin Biochem Rev"},{"key":"1346_CR70","unstructured":"ThermoFisher. Oral fluid testing. [cited June 2023]; https:\/\/www.thermofisher.com\/au\/en\/home\/clinical\/diagnostic-testing\/clinical-chemistry-drug-toxicology-testing\/drugs-abuse-testing\/drug-testing-overview\/oral-saliva-drug-test.html#2. Accessed 3 Apr 2023."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01346-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01346-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01346-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T12:18:09Z","timestamp":1710937089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01346-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01346-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"7 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/consent to publish"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. This work was supported by the Heart Lung Foundation (Davies Forsman 20190226) and the Swedish Society of Medicine (Davies Forsman 2018-1256) and Faculty of Medicine and Health Executive Dean Scholarship in Personalised Medicine (Thi Anh Nguyen). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and\/or code availability"}},{"value":"LDF and JWA conceived the idea of the paper, LDF wrote the first draft. TN and HK developed the table. All authors revised and contributed to the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution statements"}}]}}